Company Description
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics.
It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints.
The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications.
The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012.
Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
| Country | United States |
| Founded | 1983 |
| IPO Date | Nov 10, 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dr. Michael Sherman Blue F.A.C.E.P., M.D. |
Contact Details
Address: 4995 Bradenton Avenue, Suite 240 Dublin, Ohio 43017 United States | |
| Phone | (614) 793-7500 |
| Website | navidea.com |
Stock Details
| Ticker Symbol | NAVB |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000810509 |
| CUSIP Number | 63937X202 |
| ISIN Number | US63937X2027 |
| Employer ID | 31-1080091 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Craig A. Dais CPA | Chief Financial Officer and Principal Accounting Officer |
| Dr. Michael Sherman Blue F.A.C.E.P., M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 5, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jan 31, 2024 | EFFECT | Notice of Effectiveness |
| Jan 31, 2024 | EFFECT | Notice of Effectiveness |
| Jan 31, 2024 | EFFECT | Notice of Effectiveness |
| Jan 31, 2024 | EFFECT | Notice of Effectiveness |
| Jan 31, 2024 | EFFECT | Notice of Effectiveness |
| Jan 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jan 26, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |